Viridian Therapeutics (VRDN)
(Real Time Quote from BATS)
$21.80 USD
+0.63 (2.98%)
Updated Sep 25, 2024 09:54 AM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
VRDN 21.80 +0.63(2.98%)
Will VRDN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VRDN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VRDN
VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Lags Revenue Estimates
VRDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Viridian Therapeutics (VRDN): Can Its 8.7% Jump Turn into More Strength?
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates
Other News for VRDN
Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch
3 Small Biotech Stocks With The 'Big Mo' Right Now
Largest borrow rate increases among liquid names
Fairmount Funds Management LLC Expands Stake in Viridian Therapeutics Inc
Viridian Therapeutics price target raised by $9 at RBC Capital, here's why